Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multicenter, Single-Arm, Open-Label Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

NCT07080385 is registered in ClinicalTrials.gov with Calcilytix Therapeutics, Inc., a BridgeBio company as lead sponsor.

NCT NCT07080385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07080385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multicenter, Single-Arm, Open-Label Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 30, 2026
Completion date
December 31, 2030
Enrollment
28 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant hypocalcemia type 1 (adh1)